Apimeds Pharmaceuticals Sets March Effective Date for Reverse Split

Apimeds Pharmaceuticals US, Inc. ( (APUS) ) just unveiled an update.

On December 1, 2025, Apimeds Pharmaceuticals US, Inc. obtained written consent from stockholders holding a majority of its voting power to approve a one-for-ten reverse stock split of its outstanding common shares and a corresponding amendment to its certificate of incorporation. The company mailed an information statement to stockholders in March 2026 and, after a required waiting period, scheduled the reverse split to take effect at 12:01 a.m. Eastern Time on March 26, 2026, with trading on a split-adjusted basis on the NYSE American under the symbol APUS beginning that same day.

Following the effective date, every ten shares of Apimeds’ issued and outstanding common stock will automatically be combined into one share, and the stock will trade under a new CUSIP number. This capital structure change is set to alter the company’s share count and per-share price dynamics, with operational implications for shareholders’ holdings and the market trading profile of Apimeds’ common stock, while leaving the overall economic interest of investors proportionally unchanged.

More about Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc. operates in the pharmaceutical industry and is listed on the NYSE American under the symbol APUS. The company’s primary publicly traded security is its common stock, which is subject to corporate actions such as reverse stock splits that affect its share structure and trading characteristics.

Average Trading Volume: 147,970

Technical Sentiment Signal: Strong Sell

Current Market Cap: $20.37M

For an in-depth examination of APUS stock, go to TipRanks’ Overview page.